Last reviewed · How we verify
Luteal support with progesterone only
Progesterone supplementation maintains the secretory endometrium and supports early pregnancy establishment during the luteal phase.
Progesterone supplementation maintains the secretory endometrium and supports early pregnancy establishment during the luteal phase. Used for Luteal phase support in assisted reproductive technology (ART) cycles, Prevention of implantation failure and early pregnancy loss in IVF/ICSI cycles.
At a glance
| Generic name | Luteal support with progesterone only |
|---|---|
| Sponsor | Rabin Medical Center |
| Drug class | Hormone replacement therapy |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Progesterone is a naturally occurring steroid hormone essential for preparing and maintaining the uterine lining (endometrium) for embryo implantation and early pregnancy maintenance. In assisted reproductive technology (ART) cycles, exogenous progesterone is administered after ovulation to compensate for inadequate corpus luteum function and ensure adequate endometrial receptivity. This luteal phase support reduces the risk of implantation failure and early pregnancy loss.
Approved indications
- Luteal phase support in assisted reproductive technology (ART) cycles
- Prevention of implantation failure in in vitro fertilization (IVF)
Common side effects
- Breast tenderness
- Bloating
- Mood changes
- Injection site reactions (if administered intramuscularly)
Key clinical trials
- Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone (PHASE3)
- Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients (NA)
- Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles (PHASE3)
- Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation
- Addition of Gonadotropin Releasing Hormone Agonist to Luteal Phase Support (PHASE4)
- Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support (PHASE1)
- To Investigate Efficacy and Safety of a Single Injection of GenSci094 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (PHASE3)
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |